Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl) Carbamate
2. Agm 1470
3. Agm-1470
4. Agm1470
5. Caplostatin
6. Tnp 470
7. Tnp-470
8. Tnp470
1. Tnp-470
2. 129298-91-5
3. Agm-1470
4. Tnp 470
5. Agm 1470
6. O-chloroacetylcarbamoylfumagillol
7. Drg-0148
8. Nsc642492
9. Nsc-642492
10. Chembl424278
11. (3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (2-chloroacetyl)carbamate
12. Chebi:90748
13. X47gr46481
14. Carbamic Acid, N-(2-chloroacetyl)-, (3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl Ester
15. (3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl (chloroacetyl)carbamate
16. Nsc 642492
17. Ccris 8049
18. Unii-x47gr46481
19. Carbamic Acid, N-(2-chloroacetyl)-, (3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl Ester
20. Schembl1652694
21. Dtxsid0041141
22. Bdbm17446
23. Tnp-470 [mi]
24. Zinc3914617
25. Ccg-208103
26. Cs-8106
27. Db08633
28. (3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl N-(2-chloroacetyl)carbamate
29. [(3r,6r,7s,8s)-7-methoxy-8-[(2r,3r)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-2-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate
30. Nci60_014346
31. Agm-1470; Nsc 642492
32. Hy-101932
33. Tnp-470, >=98% (hplc)
34. 298t915
35. J-005665
36. Brd-k53597484-001-01-9
37. Q27097825
38. (chloroacetyl)carbamic Acid (3r,4s,5s,5r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl Ester
39. [(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate
40. Carbamic Acid, (3r,4s,5s,6r)-5-methoxy-4-[ (2r,3r)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl Ester
41. Carbamic Acid, (chloroacetyl)-, (3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl Ester
42. Carbamic Acid, (chloroacetyl)-, 5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl Ester, (3r-(3alpha,4alpha(2r*,3r*),5beta,6beta))-
| Molecular Weight | 401.9 g/mol |
|---|---|
| Molecular Formula | C19H28ClNO6 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 401.1605153 g/mol |
| Monoisotopic Mass | 401.1605153 g/mol |
| Topological Polar Surface Area | 89.7 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 636 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)
ABOUT THIS PAGE
A O-Chloroacetylcarbamoyl-Fumagillol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of O-Chloroacetylcarbamoyl-Fumagillol, including repackagers and relabelers. The FDA regulates O-Chloroacetylcarbamoyl-Fumagillol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. O-Chloroacetylcarbamoyl-Fumagillol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A O-Chloroacetylcarbamoyl-Fumagillol supplier is an individual or a company that provides O-Chloroacetylcarbamoyl-Fumagillol active pharmaceutical ingredient (API) or O-Chloroacetylcarbamoyl-Fumagillol finished formulations upon request. The O-Chloroacetylcarbamoyl-Fumagillol suppliers may include O-Chloroacetylcarbamoyl-Fumagillol API manufacturers, exporters, distributors and traders.
click here to find a list of O-Chloroacetylcarbamoyl-Fumagillol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A O-Chloroacetylcarbamoyl-Fumagillol DMF (Drug Master File) is a document detailing the whole manufacturing process of O-Chloroacetylcarbamoyl-Fumagillol active pharmaceutical ingredient (API) in detail. Different forms of O-Chloroacetylcarbamoyl-Fumagillol DMFs exist exist since differing nations have different regulations, such as O-Chloroacetylcarbamoyl-Fumagillol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A O-Chloroacetylcarbamoyl-Fumagillol DMF submitted to regulatory agencies in the US is known as a USDMF. O-Chloroacetylcarbamoyl-Fumagillol USDMF includes data on O-Chloroacetylcarbamoyl-Fumagillol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The O-Chloroacetylcarbamoyl-Fumagillol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of O-Chloroacetylcarbamoyl-Fumagillol suppliers with USDMF on PharmaCompass.
O-Chloroacetylcarbamoyl-Fumagillol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of O-Chloroacetylcarbamoyl-Fumagillol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right O-Chloroacetylcarbamoyl-Fumagillol GMP manufacturer or O-Chloroacetylcarbamoyl-Fumagillol GMP API supplier for your needs.
A O-Chloroacetylcarbamoyl-Fumagillol CoA (Certificate of Analysis) is a formal document that attests to O-Chloroacetylcarbamoyl-Fumagillol's compliance with O-Chloroacetylcarbamoyl-Fumagillol specifications and serves as a tool for batch-level quality control.
O-Chloroacetylcarbamoyl-Fumagillol CoA mostly includes findings from lab analyses of a specific batch. For each O-Chloroacetylcarbamoyl-Fumagillol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
O-Chloroacetylcarbamoyl-Fumagillol may be tested according to a variety of international standards, such as European Pharmacopoeia (O-Chloroacetylcarbamoyl-Fumagillol EP), O-Chloroacetylcarbamoyl-Fumagillol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (O-Chloroacetylcarbamoyl-Fumagillol USP).
LOOKING FOR A SUPPLIER?
